REC-1245
Recursion Pharmaceuticals: company profile
Phase 1/2 registry
Since , the date of the source that reports this phase.
Summary
REC-1245 is a program from Recursion Pharmaceuticals. It is being developed for unresectable, locally advanced or metastatic cancers; relapsed or refractory lymphomas. ClinicalTrials.gov lists it at Phase 1/2 (recruiting) under NCT06678659. The AI role named in the source is molecule design. Registry records: NCT06678659, Phase 1/2, recruiting, updated Aug 20, 2026. About the company, based in United States: Recursion OS pairs automated phenomic and other high-content biology at scale with machine learning, and since the November 2024 Exscientia combination also includes Exscientia's precision chemistry design. The latest dated source is from Aug 20, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Recursion Pharmaceuticals
- Indication
- Unresectable, locally advanced or metastatic cancers; relapsed or refractory lymphomas
- Therapeutic area
- Oncology
- AI role
- Molecule design
- Phase in the source
- Phase 1/2, as of Aug 20, 2026
- Phase source
- Registry
- Board column
- Phase 1
AI evidence
AI source: Company
“The Story of REC-1245: Recursion’s AI-Designed Cancer Drug”
Trial records
- NCT06678659 on ClinicalTrials.gov (opens in new tab) Phase 1/2 Recruiting Updated
Milestone timeline
-
ClinicalTrials.gov record: Phase 1/2
-
NCT06678659 record updated
Phase 1/2, Recruiting
About Recursion Pharmaceuticals
Recursion OS pairs automated phenomic and other high-content biology at scale with machine learning, and since the November 2024 Exscientia combination also includes Exscientia's precision chemistry design.
Spot an error? Tell me and I'll fix it.